Clinical trial
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at…
NCT00473694 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00473694 |
|---|---|
| Title | Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) |
| Official title | A Multicenter, Randomized, Parallel Group Comparative, Active-Controlled, Safety-assessor Blinded. Phase IIIa, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a Neuromuscular Block Induced by Maintenance Dosing of Rocuronium or Vecuronium at 1-2 PTCs |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anesthesia, General |
| Intervention type | Drug |
| Interventions | sugammadex, neostigmine, vecuronium, rocuronium, glycopyrrolate |
| Enrollment | 182 |
| Start date | Nov 28, 2005 |
| Primary completion | Nov 6, 2006 |
| Completion | Jan 29, 2007 |
| First posted | May 15, 2007 |
| Last update posted | Mar 19, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: